Johnson & Johnson (JNJ) Competitors

$221.36 +0.04 (+0.02%)

Closing price 03:59 PM Eastern

Extended Trading

$221.61 +0.25 (+0.11%)

As of 05:06 PM Eastern

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

Should you be buying Johnson & Johnson stock or one of its competitors? The main competitors of Johnson & Johnson include Moderna (MRNA), Novavax (NVAX), AbbVie (ABBV), Astrazeneca (AZN), and Berkshire Hathaway (BRK.B).

How does Johnson & Johnson compare to Moderna?

Moderna (NASDAQ:MRNA) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.

In the previous week, Johnson & Johnson had 35 more articles in the media than Moderna. MarketBeat recorded 79 mentions for Johnson & Johnson and 44 mentions for Moderna. Johnson & Johnson's average media sentiment score of 1.15 beat Moderna's score of 0.52 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	20 Very Positive mention(s)	9 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	59 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

75.3% of Moderna shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Moderna presently has a consensus price target of $35.73, suggesting a potential downside of 32.43%. Johnson & Johnson has a consensus price target of $252.48, suggesting a potential upside of 14.06%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67

Johnson & Johnson has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	9.52	-$2.82B	-$8.15	N/A
Johnson & Johnson	$94.19B	5.66	$26.80B	$8.65	25.59

Johnson & Johnson has a net margin of 21.83% compared to Moderna's net margin of -143.55%. Johnson & Johnson's return on equity of 32.60% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Johnson & Johnson	21.83%	32.60%	13.29%

Summary

Johnson & Johnson beats Moderna on 12 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to Novavax?

Novavax (NASDAQ:NVAX) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

Novavax has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Johnson & Johnson	21.83%	32.60%	13.29%

In the previous week, Johnson & Johnson had 36 more articles in the media than Novavax. MarketBeat recorded 79 mentions for Johnson & Johnson and 43 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.15 beat Novavax's score of 0.68 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	18 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	59 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

53.0% of Novavax shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.0% of Novavax shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novavax presently has a consensus price target of $12.13, suggesting a potential upside of 27.63%. Johnson & Johnson has a consensus price target of $252.48, suggesting a potential upside of 14.06%. Given Novavax's higher probable upside, equities research analysts plainly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.39	$440.30M	-$0.58	N/A
Johnson & Johnson	$94.19B	5.66	$26.80B	$8.65	25.59

Summary

Johnson & Johnson beats Novavax on 13 of the 16 factors compared between the two stocks.

How does Johnson & Johnson compare to AbbVie?

AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

AbbVie has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.

In the previous week, Johnson & Johnson had 19 more articles in the media than AbbVie. MarketBeat recorded 79 mentions for Johnson & Johnson and 60 mentions for AbbVie. AbbVie's average media sentiment score of 1.16 beat Johnson & Johnson's score of 1.15 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	42 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Johnson & Johnson	59 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Johnson & Johnson pays an annual dividend of $5.20 per share and has a dividend yield of 2.3%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 60.1% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years and Johnson & Johnson has increased its dividend for 64 consecutive years.

Johnson & Johnson has higher revenue and earnings than AbbVie. Johnson & Johnson is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$62.82B	5.71	$4.23B	$2.03	99.91
Johnson & Johnson	$94.19B	5.66	$26.80B	$8.65	25.59

AbbVie presently has a consensus price target of $252.90, suggesting a potential upside of 24.70%. Johnson & Johnson has a consensus price target of $252.48, suggesting a potential upside of 14.06%. Given AbbVie's stronger consensus rating and higher probable upside, equities research analysts plainly believe AbbVie is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67

Johnson & Johnson has a net margin of 21.83% compared to AbbVie's net margin of 5.79%. Johnson & Johnson's return on equity of 32.60% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-911.57%	13.43%
Johnson & Johnson	21.83%	32.60%	13.29%

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

AbbVie and Johnson & Johnson tied by winning 10 of the 20 factors compared between the two stocks.

How does Johnson & Johnson compare to Astrazeneca?

Johnson & Johnson (NYSE:JNJ) and Astrazeneca (NYSE:AZN) are related large-cap companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Johnson & Johnson has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Astrazeneca has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

In the previous week, Johnson & Johnson had 61 more articles in the media than Astrazeneca. MarketBeat recorded 79 mentions for Johnson & Johnson and 18 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 1.24 beat Johnson & Johnson's score of 1.15 indicating that Astrazeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	59 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Astrazeneca	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Johnson & Johnson pays an annual dividend of $5.20 per share and has a dividend yield of 2.3%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. Johnson & Johnson pays out 60.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 64 consecutive years.

Johnson & Johnson has higher revenue and earnings than Astrazeneca. Johnson & Johnson is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	5.66	$26.80B	$8.65	25.59
Astrazeneca	$58.74B	4.80	$10.23B	$6.66	27.31

Johnson & Johnson currently has a consensus price target of $252.48, indicating a potential upside of 14.06%. Astrazeneca has a consensus price target of $205.33, indicating a potential upside of 12.87%. Given Johnson & Johnson's higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Johnson & Johnson has a net margin of 21.83% compared to Astrazeneca's net margin of 17.19%. Johnson & Johnson's return on equity of 32.60% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Astrazeneca	17.19%	30.86%	12.68%

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 20.4% of Astrazeneca shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Johnson & Johnson beats Astrazeneca on 15 of the 19 factors compared between the two stocks.

How does Johnson & Johnson compare to Berkshire Hathaway?

Johnson & Johnson (NYSE:JNJ) and Berkshire Hathaway (NYSE:BRK.B) are related large-cap companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Johnson & Johnson has a net margin of 21.83% compared to Berkshire Hathaway's net margin of 19.31%. Johnson & Johnson's return on equity of 32.60% beat Berkshire Hathaway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.83%	32.60%	13.29%
Berkshire Hathaway	19.31%	6.55%	3.80%

Johnson & Johnson currently has a consensus price target of $252.48, indicating a potential upside of 14.06%. Berkshire Hathaway has a consensus price target of $524.50, indicating a potential upside of 9.48%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Berkshire Hathaway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	9 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.67
Berkshire Hathaway	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Johnson & Johnson has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Berkshire Hathaway has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

In the previous week, Johnson & Johnson had 53 more articles in the media than Berkshire Hathaway. MarketBeat recorded 79 mentions for Johnson & Johnson and 26 mentions for Berkshire Hathaway. Johnson & Johnson's average media sentiment score of 1.15 beat Berkshire Hathaway's score of 0.48 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	59 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive
Berkshire Hathaway	10 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 39.3% of Berkshire Hathaway shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 6.1% of Berkshire Hathaway shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Berkshire Hathaway has higher revenue and earnings than Johnson & Johnson. Berkshire Hathaway is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	5.66	$26.80B	$8.65	25.59
Berkshire Hathaway	$419.30B	2.46	$66.97B	$33.59	14.26

Summary

Johnson & Johnson beats Berkshire Hathaway on 11 of the 16 factors compared between the two stocks.

Get Johnson & Johnson News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JNJ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JNJ vs. The Competition

Export

Metric	Johnson & Johnson	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$532.86B	$289.35B	$6.18B	$22.92B
Dividend Yield	2.35%	2.84%	2.78%	4.02%
P/E Ratio	25.59	25.82	20.66	28.93
Price / Sales	5.66	4.42	527.64	24.53
Price / Cash	15.68	12.33	27.81	19.21
Price / Book	6.54	7.28	9.77	4.65
Net Income	$26.80B	$11.61B	$3.54B	$1.07B
7 Day Performance	N/A	N/A	N/A	-1.20%
1 Month Performance	-7.12%	-1.85%	6.28%	3.95%
1 Year Performance	43.76%	22.92%	41.81%	28.96%

Johnson & Johnson Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JNJ Johnson & Johnson	4.8744 of 5 stars	$221.36 +0.0%	$252.48 +14.1%	+43.6%	$532.86B	$94.19B	25.59	138,200	Positive News Analyst Revision
MRNA Moderna	1.3375 of 5 stars	$46.08 -2.6%	$35.73 -22.5%	+124.1%	$18.17B	$2.20B	N/A	4,700	Gap Up
NVAX Novavax	2.0223 of 5 stars	$7.97 -0.8%	$11.88 +49.1%	+68.8%	$1.31B	$1.12B	3.31	1,990	Earnings Report Options Volume Gap Up
ABBV AbbVie	4.9387 of 5 stars	$206.90 -0.6%	$252.90 +22.2%	+9.2%	$365.97B	$62.82B	101.96	57,000	Positive News Analyst Upgrade Analyst Revision
AZN Astrazeneca	4.0489 of 5 stars	$181.69 -1.0%	$205.33 +13.0%	N/A	$281.89B	$58.74B	27.29	96,100	Positive News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JNJ) was last updated on 5/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

How does Johnson & Johnson compare to Moderna?

Summary

How does Johnson & Johnson compare to Novavax?

Summary

How does Johnson & Johnson compare to AbbVie?

Summary

How does Johnson & Johnson compare to Astrazeneca?

Summary

How does Johnson & Johnson compare to Berkshire Hathaway?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Johnson & Johnson (JNJ) Competitors

JNJ vs. MRNA, NVAX, ABBV, AZN, and BRK.B

How does Johnson & Johnson compare to Moderna?

Which has more volatility and risk, MRNA or JNJ?

Does the media prefer MRNA or JNJ?

Do institutionals & insiders hold more shares of MRNA or JNJ?

Do analysts rate MRNA or JNJ?

Which has stronger earnings and valuation, MRNA or JNJ?

Is MRNA or JNJ more profitable?

Summary

How does Johnson & Johnson compare to Novavax?

Which has more risk and volatility, NVAX or JNJ?

Is NVAX or JNJ more profitable?

Does the media prefer NVAX or JNJ?

Do insiders and institutionals hold more shares of NVAX or JNJ?

Do analysts rate NVAX or JNJ?

Which has preferable valuation & earnings, NVAX or JNJ?

Summary

How does Johnson & Johnson compare to AbbVie?

Which has more risk and volatility, ABBV or JNJ?

Does the media favor ABBV or JNJ?

Is ABBV or JNJ a better dividend stock?

Which has higher valuation & earnings, ABBV or JNJ?

Do analysts rate ABBV or JNJ?

Is ABBV or JNJ more profitable?

Do insiders and institutionals have more ownership in ABBV or JNJ?

Summary

How does Johnson & Johnson compare to Astrazeneca?

Which has more volatility & risk, JNJ or AZN?

Does the media prefer JNJ or AZN?

Is JNJ or AZN a better dividend stock?

Which has higher earnings and valuation, JNJ or AZN?

Do analysts prefer JNJ or AZN?

Is JNJ or AZN more profitable?

Do insiders & institutionals believe in JNJ or AZN?

Summary

How does Johnson & Johnson compare to Berkshire Hathaway?

Is JNJ or BRK.B more profitable?

Do analysts prefer JNJ or BRK.B?

Which has more risk and volatility, JNJ or BRK.B?

Does the media favor JNJ or BRK.B?

Do institutionals and insiders believe in JNJ or BRK.B?

Which has higher valuation & earnings, JNJ or BRK.B?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JNJ vs. The Competition

Johnson & Johnson Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools